Which social anxiety disorder drugs are in Phase 3?

Phase 3 (or later) programs for social anxiety disorder include Fasedienol (PH94B) and VQW-765.

What are the next social anxiety disorder trial readouts?

Upcoming catalysts include Fasedienol (PH94B) (2Q 2026), VQW-765 (End of 2026), NTX-1472 (January 2027) and NTX-1472 (1H 2027).

How many clinical trials are recruiting for social anxiety disorder?

6 drug-interventional social anxiety disorder trials are currently recruiting participants, out of 96 registered interventional trials.

Anxiety & Trauma Disorders

Social anxiety disorder drug pipeline

ICD-11 6B04
MeSH D000072861

5 compounds from 5 companies are in active clinical development for social anxiety disorder, including 2 at Phase 3 or beyond.

5Compounds

5Companies

2Phase 3+

4Upcoming readouts

6Trials recruiting

Phase 3 2
Phase 2 2
Discontinued 1

Mechanisms: Small molecule (4) · Psychedelic (1)

Pipeline data compiled July 2026 · every fact sourced.

Upcoming readouts & recent results

2Q 2026AnticipatedFasedienol (PH94B)Topline dataNCT06615557
PALISADE-4 topline anticipated 2Q 2026; randomized portion complete. ↗
End of 2026AnticipatedVQW-765Topline dataNCT07221578
Phase 3 VQW-765 social anxiety disorder topline results expected by end of 2026 ↗
January 2027AnticipatedNTX-1472Registry resultsNCT07323784
ClinicalTrials.gov estimated primary completion of the SOAR Phase 2 study (NCT07323784): January 2027 (estimated study completion also January 2027). ↗
1H 2027AnticipatedNTX-1472Topline dataNCT07323784
Topline data from the Phase 2 SOAR proof-of-concept study of NTX-1472 210 mg once daily versus placebo in generalized social anxiety disorder — safety/tolerability primary, LSAS the key efficacy secondary — expected 1H 2027. ↗
2025-12-17ReportedFasedienol (PH94B)Topline datamissedNCT06358651
PALISADE-3 missed its primary SUDS endpoint (large placebo response); no secondary difference. ↗
2025-10-20ReportedBNC210 (soclenicant)Topline datamissedNCT06510504
Phase 3 AFFIRM-1 missed its primary SUDS endpoint in social anxiety disorder; Neuphoria discontinues the SAD program. ↗
2023-08-07ReportedFasedienol (PH94B)Topline datametNCT05011396
PALISADE-2 met primary SUDS (p=0.015) and key secondary CGI-I (p=0.033) endpoints. ↗
2022-12-02ReportedVQW-765Topline datamissedNCT04800237
Phase 2 VQW-765 performance-anxiety study missed primary endpoint overall; significant in females ↗

See the full catalyst calendar →

Compounds in development (5)

Compound	Company	Phase	Status	Mechanism
Fasedienol (PH94B)Fast Track	Vistagen Therapeutics, Inc.	Phase 3	Active	Nasal chemosensory receptor neurons Agonist
VQW-765	Vanda Pharmaceuticals Inc.	Phase 3	Recruiting	alpha7 nAChR Partial agonist
EMP-01 (oral R-MDMA)	EmpathBio, Inc.	Phase 2	Completed	SERT Releaser
NTX-1472	Newleos Therapeutics, Inc.	Phase 2	Recruiting	V1a receptor Antagonist
BNC210 (soclenicant)	Neuphoria Therapeutics, Inc.	Discontinued	Discontinued	alpha7 nAChR NAM

Trials recruiting now (6)

6 drug-interventional social anxiety disorder trials recruiting now, of 96 registered interventional trials. Browse all on ClinicalTrials.gov →

Phase 4Investigating the Effects of Cannabidiol on Social Anxiety Disorder
Cannabidiol, Placebo
Massachusetts Institute of Technologyn=50United States · 1 siteStarted Jul 2025NCT05649059
Phase 4Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder
Sertraline (Oral Antidepressant)
Emine Kanmazn=56Turkey (Türkiye) · 1 siteStarted Nov 2024NCT07192367
Phase 3A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder
VQW-765, Placebo
Vanda Pharmaceuticals Inc.n=500United States · 30 sitesStarted Sep 2025Tracked: VQW-765 NCT07221578
Phase 2A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder (SOAR)
NTX-1472, Placebo
Newleos Therapeutics, Inc.n=100United States · 11 sitesStarted Dec 2025Tracked: NTX-1472 NCT07323784
Phase 2A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray
VistaGen Therapeutics, Inc.n=60United States · 9 sitesStarted Jan 2025NCT06809179
UnknownNeural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety
Sertraline
Boston University Charles River Campusn=240United States · 1 siteStarted May 2023NCT05683223

Frequently asked

How many drugs are in development for social anxiety disorder?: 5 compounds from 5 companies are in active clinical development for social anxiety disorder, including 2 at Phase 3 or beyond.
Which social anxiety disorder drugs are in Phase 3?: Phase 3 (or later) programs for social anxiety disorder include Fasedienol (PH94B) and VQW-765.
What are the next social anxiety disorder trial readouts?: Upcoming catalysts include Fasedienol (PH94B) (2Q 2026), VQW-765 (End of 2026), NTX-1472 (January 2027) and NTX-1472 (1H 2027).
How many clinical trials are recruiting for social anxiety disorder?: 6 drug-interventional social anxiety disorder trials are currently recruiting participants, out of 96 registered interventional trials.